What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Leerink Partnrs increased their FY2026 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of $1.15 for the year, up from their prior forecast of $1.09. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.51 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.35 EPS.

Other analysts have also issued research reports about the company. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday. StockNews.com raised ACADIA Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, September 13th. Raymond James reaffirmed a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Cantor Fitzgerald cut their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an "overweight" rating for the company in a research note on Wednesday, August 7th. Finally, Morgan Stanley lowered shares of ACADIA Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $28.00 to $20.00 in a research note on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $25.56.

ACADIA Pharmaceuticals Stock Up 3.5 %

Shares of ACAD stock traded up $0.61 on Monday, reaching $18.27. The stock had a trading volume of 1,430,975 shares, compared to its average volume of 1,689,055. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $32.59. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of 22.64 and a beta of 0.38. The firm's 50-day moving average is $15.45 and its two-hundred day moving average is $15.97.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.06. The business had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 27.29%. The firm's revenue for the quarter was up 18.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.40) earnings per share.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Park Place Capital Corp purchased a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth about $25,000. Values First Advisors Inc. bought a new stake in ACADIA Pharmaceuticals during the third quarter valued at approximately $27,000. Covestor Ltd increased its stake in shares of ACADIA Pharmaceuticals by 70.5% in the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 840 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter worth $48,000. Finally, Quest Partners LLC raised its holdings in ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 1,047 shares during the period. 96.71% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Brendan Teehan sold 9,534 shares of the business's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the completion of the transaction, the chief operating officer now owns 52,177 shares of the company's stock, valued at approximately $797,264.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Brendan Teehan sold 9,534 shares of the business's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the completion of the sale, the chief operating officer now directly owns 52,177 shares in the company, valued at approximately $797,264.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen Davis sold 31,747 shares of the firm's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $485,094.16. Following the transaction, the chief executive officer now directly owns 186,555 shares in the company, valued at $2,850,560.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,014 shares of company stock worth $779,494 in the last three months. Corporate insiders own 28.30% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.